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Abstract: Vaccine safety surveillance is essential in vaccination programs. We accomplished a 
descriptive study of surveillance AEFI-reporting rate in human papillomavirus (HPV) vaccine 
administered in the Valencian Community, Spain. Data were obtained from Spanish 
Pharmacovigilance Adverse Reactions Data (FEDRA). Reporting rates were calculated using local 
net doses distributed as the denominator. Trends were assessed using joinpoint regression with 
annual percent change (APC) reported. The AEFI-reports decreased between 2008 and 2018 in two 
periods, a fast decreasing rate from 2009 to 2011 (from 192.2 to 24.93 per 100000 doses; APC, 
−54.9%; 95%CI [−75.2; −17.7]), followed by a stable trend (−13% APC, 95%CI [−26.1; 2.4]). For the 
age group analysis, only the group aged 14–15 years old followed the same trend with -58.4% 
(95%CI [−73.9; −33.8]) APC during 2008–2011, and −8.8% (95%CI [−27.7; 15]) APC during 
2011-2018. The majority of the reports (73.82%) were nonserious, involving reactions at or near the 
vaccination site, headache, and dizziness events. No death was reported. AEFI-reporting rates for 
HPV immunization in the Valencian Community have decreased considerably with two trend 
periods observed for girls aged 14–15 years old. Currently, the AEFI reporting rate shows a 
decreasing trend, perhaps following the Weber effect, and it could also be affected by media 
attention and coverage. 
Keywords: adverse events following immunization (AEFIs); Human Papillomavirus vaccines; 
Spanish Pharmacovigilance System; vaccine safety; postlicensure surveillance 
 
1. Introduction 
The World Health Organization recommends the human papillomavirus (HPV) vaccine for the 
prevention of cervical cancer and other diseases preventable by HPV vaccination [1].  
The introduction of HPV vaccines into childhood vaccination programs shows compelling 
evidence of their substantial impact on HPV infection rates and the resulting fewer cases of genital 
warts, also providing excellent protection against cervical intraepithelial neoplasia among the 
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population [2,3], and in situ adenocarcinoma associated with HPV16/18 infection in young women 
who were not initially infected [4]. Further, programs with multicohort vaccination and high 
vaccination coverage have had a greater and direct impact and positive herd effects [3].  
The safety and tolerability of each HPV vaccine have been studied extensively in prelicensure 
clinical trials with similar profiles in the vaccinated and control groups, irrespective of age or 
ethnicity [5–10]. However, as the risk perception of diseases preventable by HPV decreases because 
of successful immunization programs, the risk perceived of the adverse events following 
immunization (AEFI) may increase [11], and for these reasons, postlicensure vaccine safety 
monitoring and evaluation programs play an important role in maintaining the public trust and the 
support of vaccination programs [12].  
Adverse event reports have been collected and pooled into large databases in different 
countries in order to identify rare safety concerns in a timely fashion [13]. Spain has a national 
health system with universal access funded from general taxation; it is decentralized, and the 
country’s 19 regions (17 Autonomous Communities and two Autonomous Cities) are responsible 
for the management and delivery of vaccination programs [14]. Currently in Spain, three HPV 
vaccines are available: a bivalent (bHPV), a quadrivalent (qHPV), and a nonavalent vaccine 
(nHPV).  
The Ministry of Health leads and coordinates the Interterritorial Council and the Commission 
on Public Health. The Interterritorial Council is Spain's main decision-making institution for the 
coordination of all vaccine programs and the Commission on Public Health and makes 
recommendations or proposes public health programs [14]. In September 2007, the HPV vaccination 
program was approved by the Commission on Public Health and by the Interterritorial Council in 
October that same year [15]. The Autonomous Communities implemented the HPV vaccine during 
2007–2008, with some choosing the qHPV vaccine (Gardasil) and others the bHPV vaccine 
(Cervarix)[14]. 
In October 2008, the HPV vaccine was implemented in the Valencian Community 
immunization programs for females aged 14 years old with three doses of the qHPV vaccine 
(Gardasil) [16] and was administered in healthcare centers and schools [14].  
In 2011, this authorization was modified and the Valencian Community immunization 
programs changed the qHPV vaccine (Gardasil) for the bHPV vaccine (Cervarix) [17]. In 2015, a 
new modification, the reduction of doses, was introduced, and the vaccination was extended to 
girls aged 12 years old [16,18].  
The Valencian Community has about five million inhabitants [19] and a successful vaccination 
program with high vaccination coverage, and in 2019, this was estimated to be 87.7% for girls born 
in 2006 for the first dose, and 73.4% for the second dose, showing a slight decrease compared to 
previous years [20].   
In February 2009, there were two reported cases of status epilepticus with myoclonus in two 
girls after the administration of the second dose of the qHPV vaccine (Gardasil) at schools in the 
same city of the Valencian Community [14,21]. Those cases were extensively covered by all media 
at the regional and national levels [22]. Subsequently, in 2013, a study described the suspected 
adverse reactions following the HPV vaccine during the first four years of HPV vaccination [23].  
The objective of this study is to summarize the trends in rates of adverse events attributable to 
HPV vaccine use in the Valencian Community from January 2008 to December 2018. 
2. Materials and Methods  
2.1. Data Source 
The data for this study come from the “Spanish Pharmacovigilance Adverse Reactions Data” 
(FEDRA) of the “Spanish Pharmacovigilance System for Medicinal Products for Human Use” 
(SEFV-H), managed by the “Spanish Agency for Medicines and Health Products” (AEMPS). 
SEFV-H gathers data from the 17 autonomous pharmacovigilance centers plus the AEMPS. Each 
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Autonomous Community is responsible for evaluating and registering the adverse effects 
suspected from the use of a specific drug in a FEDRA database [24,25].  
The FEDRA is a passive reporting system that relies on individuals sending reports about their 
experiences to SEFV-H. It is designed to allow the detection of unusual or unexpected patterns of 
adverse event reporting, not for determining if a vaccine or drug causes a health problem. 
The information collected in the FEDRA database comes from a wide array of sources, 
including patients and parents, state health agencies, pharmacies, health care providers, and the 
makers of the drugs including vaccines [25], who complete each AEFI report.  
In the Valencian Community since 2000, all immunizations events have been recorded in the 
Vaccination Information System (SIV), including AEFI reports [26], and since 2005 that system has 
been a population-based individual register linked to the FEDRA, and only health care workers 
have access to this platform. All AEFI reports are evaluated and uploaded to the FEDRA by 
technicians from the Valencian Community Pharmacovigilance Center. 
2.2. Data Extraction 
The FEDRA and SIV reporting forms include information about the event, collecting data such 
as time of onset following immunization, outcome, hospitalization dates, patient identifiers (age, 
sex), and the vaccine characteristics (type, name, and administration route), vaccine antigens, 
vaccination date, and dose number. Typically, each AEFI report lists several symptoms, signs, and 
diagnoses that had been recoded from the reporter’s description into standardized terms using the 
Medical Dictionary for Regulatory Activities (MedDRA® )[27]. 
We received SEFV-H (AEMPS) authorization to analyze the FEDRA database regarding the HPV 
vaccine in the Valencian Community from 1 January 2008, through 31 December 2018. The results, 
discussion, and conclusions of this paper show the authors’ point of view, and they do not 
represent in any way the position of the SEFV-H or the AEMPS regarding this issue. 
2.3. Descriptive Analysis  
Rates of AEFI reports per 100,000 doses of HPV vaccine administered among the population of 
interest over the period between 1 January 2008 and 31 December 2018 were calculated. The 
denominator data utilized to estimate AEFI reporting rates were obtained from the national HPV 
vaccine coverage survey for ages 11–49 years old. The rates of AEFI reports were also analyzed by 
age group at the time of vaccination: 11 to 13 years old, 14 to 15 years old, 11 to 15 years old, and 
<15 years old. 
The confidence intervals for the AEFI reporting rates were calculated by assuming a Poisson 
distribution and by applying the modified Wald method [28] if the rate numerator was zero. 
To analyze the additional diagnoses or symptoms listed in more than one percent of AEFI 
records (e.g., headache, dizziness), additional terms were created. Reaction terms listed in less than 
one percent of records were grouped into broader categories based on the organ system where the 
reaction was manifested (e.g., gastrointestinal, neurological). 
2.4. Trend Analysis  
A joinpoint regression analysis was used to determine time segments and time points in AEFI 
trends for each age group. Each joinpoint (if any) showed a significant change in trend and an 
annual percentage of change (APC) of the rates, and the corresponding confidence interval at 95% 
(CI 95%) was computed from each trend segment. A negative APC indicated a decreasing trend. 
The year 2008 was excluded from these analyses, since the detection of a point of change in the 
trend was substantially affected by this year’s data. To build the model, the National Cancer 
Institute’s freeware Joinpoint Regression Program V 4.7.0.0 was used [29], under the usual 
assumption of heteroscedastic variances for the rates. The weighted least square method was used 
to estimate the model. The Monte Carlo permutation test [30] was used to prove the existence of 
statistically significant joinpoints (p < 0.05). This test is usually used in studies of rate trends. 
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2.5. Ethical Statement 
The data collected in the FEDRA are monitored by the SEFV-H and managed by AEMPS. 
SEFV-H consolidates the health administration activities, which are executed permanently to 
collect, elaborate, and process the information about suspicions of adverse reactions to identify 
unknown risks or changes in known risks. Further, the SEFV-H manage studies as is deemed 
necessary to confirm or quantify said risks [24]. Finally, AEFI reporting is a routine surveillance 
program which does not require informed consent and uses depersonalized, de-identified data. 
3. Results  
Between 1 January 2008 and 31 December 2018, 664,722 bHPV, qHPV, and nHPV vaccinations 
were administered in the Valencian Community according to the Vaccination Information System 
(SIV) [20]. 
A total of 812 adverse events were recorded in the SEFV-H database (FEDRA), corresponding 
to 317 individual AEFI reports, with a mean of 73.81 (SD 84.31) per year; the minimum was 10 in 
2017 and the maximum 296 in 2009. There were 2.57 events per AEFI report. The overall AEFIs 
reporting rate was 47.54 notifications per 100,000 vaccine doses distributed (Table 1).  
The AEFI reports concerned 65.51% qHPV, 34.18% bHPV, 0.32% nHPV; girls aged between 12 
to 17 years old reported 94.45% of AEFIs. The primary reporters were submitted by health 
professionals (98.48%), and only 1.5% were submitted by patients or their lawyers. 
Table 1. Adverse events following immunization (AEFI) reporting rate following human 
papillomavirus (HPV) immunizations in the Valencian Community, Spain (2008–2018). 
Years AEFIr Doses 
AEFIr 
Rate 1 
95%CI 
Total 
AE 
AEFIr with 
Serious AE 
Total 
Serious 
AE 
Total 
AE/ 
AEFIr 
Total AE 
Serious 
/AEFIr 
AEFIr 
Serious 
Rate 1 
2008 41 30,112 136.16 94.48–177.84 154 18 110 3.76 2.68 59.78 
2009 110 57,233 192.2 156.28–228.11 296 24 134 2.69 1.22 41.93 
2010 43 58,201 73.88 51.80–95.96 93 13 29 2.16 0.67 22.34 
2011 17 68,089 24.97 13.10–36.84 36 6 22 2.12 1.29 8.81 
2012 27 62,257 43.37 27.01–59.73 57 3 7 2.11 0.26 4.82 
2013 24 64,126 37.43 22.45–52.40 56 8 24 2.33 1.00 12.48 
2014 16 49,019 32.64 16.65–48.63 34 2 10 2.13 0.63 4.08 
2015 13 70,180 18.52 8.45–28.59 34 6 21 2.62 1.62 8.55 
2016 7 78,761 11.04 2.30–15.47 15 1 1 1.43 0.43 1.27 
2017 7 63,402 9.46 1.89–17.04 10 1 3 1.67 0.50 1.58 
2018 12 63,342 18.94 8.23–29.66 27 1 1 2.25 0.08 1.58 
Total  317 66,4722 47.54 42.30–52.78 812 83 362 2.57 1.14 12.49 
1 Reports per 100 000 doses distributed; AEFIr: Adverse events following immunization report; AE: 
Adverse event. 
3.1. Trends over Time by Setting 
Throughout the study period (2008–2018), we observed that forty-seven percent (47.78%, n = 
151/317) of the total AEFI-reports was received mainly in 2008 and 2009, the first years of the HPV 
vaccination program in the Valencian Community. The AEFI reporting rate in 2009 was the highest 
among girls aged 14 to 15 years old (217.75 per 100,000 doses [CI 95% (176.1–259.4)]; this group also 
received the greatest number of vaccinations. Regarding the overall population-based reporting 
rate per 100,000 doses, we found a decreasing trend from 2009 (192.2 [156.28–228.11]) to 2017 (9.46 
[1.89–17.04]). Figure 1 shows the reporting rates of AEFI reports following immunization per 
100,000 by age group. 
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Figure 1. AEFI reporting rates per 100,000 by age group in the Valencian Community, Spain 
(2008–2018). 
3.2. Trend in AEFI Notifications by Age According to the Joinpoints Identified by the Analysis 
We observed a decline in the AEFI reporting rates for HPV vaccines; there was one significant 
joinpoint in 2011 (p = 0.022), and two periods were identified. The first period, between 2009 and 
2011, has a decreasing trend (−54.9% annual change, 95%CI [−75.2; −17.7]), and it was followed by a 
flat, plain trend between 2011 and 2018 (−13% APC, 95%CI [−26.1; 2.4]), with a nonsignificant 
decrease.  
We analyzed the APC and joinpoints separately according to different age groups but found 
no joinpoints in either the 11–13 years old and older than 15 years old groups. However, one 
significant joinpoint was identified in the 14–15 years old group in 2011 (p = 0.006), leading to two 
periods with different trends; the fast descending trend in the AEFI reporting rates was in the 
2009–2011 period, with −58.4% (95%CI [−73.9; −33.8]) APC, while the trend in the second period, 
2011–2018, was −8.8% (95%CI [−27.7; 15]) APC. The fast descending trend in the rates observed in 
the group as a whole could be explained by the AEFI reporting rate trend of girls aged 14–15 years 
old. Results from selected age groups are displayed in Figure 2. (See Table A1). 
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Figure 2. Trends in AEFI reporting rates following HPV vaccines in the Valencian Community, 
Spain, according to the joinpoints identified by the analysis by different age groups. (a) 11–13 years 
old group, no joinpoint was detected; (b) 14–15 years old group, a joinpoint was detected in 2011; (c) 
> 15 years old group, no joinpoint was detected; (d) for all the groups, a joinpoint was detected in 
2011. 
3.3. The Trend of AEFIs Reported as ‘Serious’ 
The rate of serious events was calculated using the total number of AEFI reports with some 
adverse events classified as serious, and the number of doses as the denominator. A total of 83 AEFI 
reports (26.18%) from 317 were recorded as serious events, and more than 20% (65/317) were 
generated in the first three years of the HPV vaccination program in the Valencian Community. The 
rate of serious AEFI reports for HPV vaccines was 12.49 per 100,000 doses (Table 1). 
In the period of the study, there were 1.14 serious events per AEFI report, 44.58% (362/812) 
were reported as a serious adverse event, and about thirty percent (29.8% (242/812)) were recorded 
as recovered or recovering at the moment of reporting. Not a single death was recorded in eleven 
years of surveillance.  
Figure 3 shows the trend of the percentage AEFIs reported as serious overall AEFI reports. 
From 2008 to 2018 in the Valencian Community, the percentage of serious events for the vaccines 
administered declined in 2018 as compared with the earlier years, following reductions in the 
number of AEFIs notified. Although the global trend of AEFIs reports fell, the trend of the 
percentage of AEFIs reported as a serious event seems to remain nearly constant. 
(a) (b) 
(c) (d) 
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Figure 3. Trend of the percentage of serious AEFI reports in relation with the total AEFI reports in 
the Valencian Community, Spain (2008–2018). 
3.4. Events Following Immunization Reactions 
Table 2 shows the top 11 AEFIs for HPV vaccines. The most frequently reported adverse events 
were injection site reaction (10.1% of 812 AEFI records) followed by headache (9.7%), dizziness 
(8.8%), and fever (7.6%). One case was reported as disability with deafness without information 
related to recovery, there was a case of bronchospasm, another with optic neuropathy, and one case 
of hepatitis, none with information of recovery or surveillance. 
Table 2. Distribution and frequency of reactions listed in AEFI records. 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 
AEFI a (n) (n) (n) (n) (n) (n) (n) (n) (n) (n) (n) 
Injection site reaction b 8 24 11 6 9 4 2 1 6 3 8 
Headache 7 33 6 4 7 11 3 5 2 0 1 
Dizziness 12 32 7 2 0 3 6 4 1 1 4 
Fever  2 26 12 6 7 9 2 3 1 2 0 
Syncope  11 21 12 3 5 2 3 3 1 0 1 
Myalgia and malaise 1 16 6 2 4 3 1 6 1 2 1 
Nausea/ vomiting 4 20 4 1 3 4 3 1 0 0 1 
Presyncope/Pallor 6 11 2 1 2 0 3 1 1 1 5 
Hypersensitivity reaction c 3 11 5 0 6 1 2 1 0 1 1 
Seizure 0 9 3 0 1 2 0 0 0 0 0 
Somnolence 3 4 2 1 1 0 0 1 0 0 1 
Others 97 89 23 10 12 17 9 8 2 0 4 
Total 154 296 93 36 57 56 34 34 15 10 27 
Abbreviations: AEFI, adverse event following immunization; a using MedDRA terms. More than 1 
code may be assigned to a single report; b local injection site reaction MedDRA codes include 
injection site abscess, injection site abscess sterile, injection site atrophy, injection site cyst, injection 
site desquamation, injection site hemorrhage, injection site hypersensitivity, injection site 
inflammation, injection site mass, injection site necrosis, injection site nodule, injection site edema, 
and injection site pain; c hypersensitivity reaction MedDRA codes include anaphylactic reaction, 
anaphylactic shock, anaphylactoid reaction, cross-sensitivity reaction, dermographism, 
hypersensitivity, urticaria, urticaria thermal, and urticaria vesicular. 
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4. Discussion 
Pharmacovigilance is a critical component of healthcare for determining the benefit to risk 
ratio of treatment and the monitoring of vaccine safety in order to ensure patient and parent trust. 
As expected when introducing a new vaccine, the AEFI reporting rate for HPV vaccine was very 
high in 2009 (192.2 per 100,000 doses), and the highest annual number of cases (n = 110; 34.7%) was 
found in the Valencian Community during the first 10 years of this vaccine’s administration. 
Historical data in some countries [31–33] show that initial high levels of AEFI reporting occur each 
time a new vaccine is introduced, as immunization providers are more likely to report milder, less 
serious AEFIs for vaccines they are not familiar with, followed by a reduction and stabilization of 
reporting over time (Weber effect) [34]. This enhanced propensity to report events following newer 
vaccines increases the sensitivity of the system for detecting signals of serious, rare or previously 
unknown events. 
Current data held by the FEDRA in the Valencian Community indicate that the annual number 
of reports decreased substantially in the following 10 years (from 110 AEFIs reports in 2009 to 12 in 
2018). 
There are some reasons that can explain this reduction and stabilization trend of AEFI 
reporting. First, the Weber effect could be potentiated by the two cases reported in February 2009 
(early years of the new HPV vaccine). Those cases came to the attention of the media and resulted 
in considerable media interest both locally and internationally [21,22], which could have affected 
the following years’ AEFIs report ratio until 2011, when a change in trend occurred, as it is in this 
year that the health authorities changed the qHPV vaccine for the bHPV vaccine [14,17].  
The change in the cohort age from 14-year-olds to 12-year-olds of the Valencian Community 
vaccination program could have decreased the AEFI reports that were mainly related to anxiety, as 
shown in a systematic review by Loharikar et al. [35], which described a high incidence of 
anxiety-related AEFI clusters in adolescents.  
Currently, the acceptance for the HPV vaccine is high [36], and the reports related to the 
controversy in which it was involved during the first years of the vaccination program have 
decreased. This more lenient social environment could have an influence on the risk perception of 
the potential informers when faced with an AEFI. 
The trend analysis of the AEFI reporting rate from 2008 to 2018 showed a drop with a joinpoint 
in 2011, and during the first three years (2008–2010), the rate was around 100 AEFIr per 100,000 
doses, as described in Slovenia [37] and the UK [38] ,but higher than in other countries in the early 
years of the vaccination program [33,37,39–44]. However, since 2011, the trend has seen a stabilized 
period with little APC, and currently, in the Valencian Community, the AEFI reporting rate after 
HPV immunization is low and consistent with rates of events seen elsewhere and in different 
regions [43,45–47]. 
The rate of reports submitted declined in 2016 and 2017 but slightly increased in 2018, 
although more years of monitoring are needed in order to evaluate if this could represent a new 
joinpoint. 
In our study, the rate for serious AEFIs was also higher in the first three years in the Valencian 
Community (more than 20 AEFIr per 100,000 doses), although this rate was slightly higher than in 
other countries [37,47]. However, the exposure by the press could have contributed to this 
phenomenon [48,49]. The last few years seemed to have had a more stable situation, with a 
reporting rate similar to those of other countries [41,46,50,51].  
The AEFIs most commonly reported, which were milder in nature (such as headache, 
dizziness, myalgia, and malaise), are consistent with those of other studies [33,37,41,44,46,47,52–54] 
and usually related or accompanied by anxiety symptoms [37,46,55]. On the other hand, the 
emotional component of the adolescent population (fear, anxiety) when facing vaccination is known 
[35,56,57], which could have had a negative impact on the vaccination process.  
In the analysis according to age groups, we found that the AEFI reports rate was influenced by 
the 14-15-year-old adolescent girls, with this group being the largest recipient of HPV vaccines, 
which determined the trend change in 2011. Additionally, until that year, the vaccination was 
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carried out mainly in schools, and the media effect of the cases in 2009 had remained in the 
collective memory. Further, in 2011, the change in the type of vaccine took place. In our study, we 
could not verify if the vaccination center (school or health center) influenced the AEFI reporting 
rate. We believe that the fear of HPV vaccination, a common experience among adolescents [56,58], 
could have increased the AEFI reporting rate.  
This study does not exclude the presence of rare AEFI following HPV vaccination, such as 
complex regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS), and 
chronic fatigue syndrome (CFS), because our data come from a passive reporting system and the 
information in general are disaggregates, with these diagnoses being generally poorly understood 
and under-recognized. Further, a larger sample is needed for performing a cluster analysis [53,54]. 
The major limitation of a passive surveillance system such as the one available in the Valencian 
Community is that it can only identify early warning signals and neither can it estimate the risk 
related to an unexposed population nor does it exclude risks with a good degree of certainty [41,59]. 
Moreover, the diagnoses in our study were not validated by a review of the patient records because 
this information was not made available for review; therefore, we were unable to validate AE 
reports independently. The FEDRA accepts all reports without judging whether the event was 
caused by the vaccine [25].  
The AEFI reporting ratio is useful for benchmarking and following trends over time; however, 
this ratio does not provide information on the quality of the reporting system and does not 
guarantee the capacity to detect and manage a vaccine safety problem at a national level [60]. 
However, this analysis allows us to recognize the possible impact of changes in the strategies of a 
national/regional vaccination program. Additional efforts are required to ensure and improve data 
quality, AEFI reporting, and surveillance of immunization safety in our community. 
5. Conclusions  
The trend on AEFI reporting rate after HPV immunization in the Valencian Community 
comprised two periods, an earlier one with a faster decrease followed by a stable period, explained 
only by the AEFI reporting rate in the group of girls aged 14–15 years old. Currently, the AEFI 
reporting rate shows a decreasing trend following a possible Weber effect and could be affected by 
media attention and coverage. The health authorities should improve the training of the potential 
users of the system of declaration of adverse effects in order to avoid ambiguous terms and to 
increase the quality of the reports. 
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Appendix A 
Table A1. Trends in AEFI reporting rate following HPV immunizations in the Valencian Community, Spain according to age group. 
 11 to 13 Years Old 14 to 15 Years Old >15 Years Old * 
Years ICSR Doses AEFI Rate 95%CI ICSR Doses AEFI Rate 95%CI ICSR Doses AEFI Rate 95%CI 
2008 2 2424 82.51 9.99–298.05 32 18,875 169.54 110.8–228.28 7 8813 79.43 31.93–163.65 
2009 0 1003 0 0.00–367.78 105 48,220 217.75 176.10–259.4 5 8010 62.42 20.27–145.67 
2010 2 3217 62.17 7.53–224.58 41 51,121 80.2 55.65–104.75 0 3863 0 0.00–95.49 
2011 0 9130 0 0.00–40.40 16 54,350 29.44 15.01–43.86 1 4609 21.7 0.55–120.89 
2012 7 11,494 60.9 24.49–125.48 20 46,171 43.32 24.33–62.30 0 4592 0 0.00–80.33 
2013 6 13,418 44.72 16.41–97.33 15 45,625 32.88 16.24–49.51 3 5083 59.02 12.17–172.48 
2014 2 10,083 19.84 2.40–71.65 13 33,958 38.28 17.47–59.09 1 4978 20.09 0.51–111.93 
2015 8 34,885 22.93 9.90–45.19 4 29,914 13.37 0.27–26.48 1 5381 18.58 0.47–103.54 
2016 5 56,405 8.86 2.88–20.69 1 17,283 5.79 0.00–17.13 1 5073 19.71 0.50–109.83 
2017 4 47,565 8.41 2.29–21.53 1 10,241 9.76 0.00–28.90 1 5596 17.87 0.45–99.56 
2018 10 46,685 21.42 10.27–39.39 2 8475 23.6 0.00–56.31 0 8182 0 0.00–45.09 
Total 46 236,309 19.47 13.84–25.09 250 364,233 68.64 60.13–77.15 20 64,180 31.16 17.50–44.82 
(*) 95% confidence interval. In women aged over 15 years old, the limits have been calculated exactly (except for the period as a whole). 
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